Opaleye Management Inc. Acquires Shares of 375,204 OKYO Pharma Limited Sponsored ADR $OKYO

Opaleye Management Inc. acquired a new stake in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 375,204 shares of the company’s stock, valued at approximately $563,000. Opaleye Management Inc. owned 0.71% of OKYO Pharma at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Citadel Advisors LLC acquired a new position in shares of OKYO Pharma in the 3rd quarter valued at $31,000. XTX Topco Ltd acquired a new stake in OKYO Pharma during the 4th quarter worth $36,000. Finally, Renaissance Technologies LLC grew its position in OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after purchasing an additional 96,800 shares during the last quarter. 2.97% of the stock is currently owned by hedge funds and other institutional investors.

OKYO Pharma Trading Down 1.4%

Shares of OKYO Pharma stock opened at $1.43 on Friday. OKYO Pharma Limited Sponsored ADR has a 52-week low of $1.34 and a 52-week high of $3.20. The company’s 50-day simple moving average is $1.55 and its 200-day simple moving average is $1.59.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. HC Wainwright dropped their price objective on shares of OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, July 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, OKYO Pharma currently has an average rating of “Hold” and an average target price of $5.67.

OKYO Pharma Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.